Ainos Inc. (Ainos), formerly Amarillo Biosciences Inc., is a healthcare and biotechnology company advancing next-generation point-of-care testing (POCT), therapeutics based on very low-dose interferon alpha (VELDONA), and synthetic RNA–driven preventative medicine. The company’s mission is to improve access to timely diagnosis and targeted treatment through telehealth-friendly diagnostics and immunomodulatory therapies for both human and animal health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ainos is engaged in the research and development of drug candidates such as VELDONA, which involves significant investment and complexity. The company focuses on discovering new products and developing additional uses for existing products to maintain business strength. It is also developing AI Nose programs and VELDONA drug candidates, with a history of conducting 68 human clinical studies evaluating low-dose oral interferon alpha. The company operates primarily in Taiwan, leveraging the region's skilled workforce and technology supply chain. The company operates its research and development and certain operating functions primarily in Taiwan. This unit is responsible for managing the company's R&D activities, supporting commercialization efforts, and coordinating with manufacturing partners, distributors, and customers in the region. The company’s intellectual property portfolio includes issued patents and pending patent applications covering core technologies such as AI Nose sensing technologies, point-of-care testing, and interferon-based therapeutics. The issued patents have expiration dates ranging from 2026 to 2046. The company is developing VELDONA drug candidates and AI Nose programs. In FY2025, the company spent US$7.7 million on its R&D activities, which declined 7.8% YoY.